Literature DB >> 9670993

Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS.

E D Hall1, P K Andrus, J A Oostveen, T J Fleck, M E Gurney.   

Abstract

Transgenic mice that overexpress a mutated human CuZn superoxide dismutase (SOD1) gene (gly93-->ala) found in some patients with familial ALS (FALS) have been shown to develop motor neuron disease, as evidenced by motor neuron loss in the lumbar and cervical spinal regions and a progressive loss of voluntary motor activity. The mutant Cu,Zn SOD exhibits essentially normal dismutase activity, but in addition, generates toxic oxygen radicals as a result of an enhancement of a normally minor peroxidase reaction. In view of the likelihood that the manifestation of motor neuron disease in the FALS transgenic mice involves an oxidative injury mechanism, the present study sought to examine the extent of lipid peroxidative damage in the spinal cords of the TgN(SOD1-G93A)G1H mice over their life span compared to nontransgenic littermates or transgenic mice that overexpress the wild-type human Cu,Zn SOD (TgN(SOD1)N29). Lipid peroxidation was investigated in terms of changes in vitamin E and malondialdehyde (MDA) levels measured by HPLC methods and by MDA-protein adduct immunoreactivity. Four ages were investigated: 30 days (pre-motor neuron pathology and clinical disease); 60 days (after initiation of pathology, but predisease); 100 days (approximately 50% loss of motor neurons and function); and 120 days (near complete hindlimb paralysis). Compared to nontransgenic mice, the TgN(SOD1-G93A)G1H mice showed blunted accumulation of spinal cord vitamin E and higher levels of MDA (P < 0.05 at 30 and 60 days) over the 30-120 day time span. In the TgN(SOD1)N29 mice, levels of MDA at age 120 days were significantly lower than in either the TgN(SOD1-G93A)G1H or nontransgenic mice. MDA-protein adduct immunoreactivity was also significantly increased in the lumbar spinal cord at age 30, 100, and 120 days, and in the cervical cord at 100 and 120 days. The results clearly demonstrate an increase in spinal cord lipid peroxidation in the FALS transgenic model, which precedes the onset of ultrastructural or clinical motor neuron disease. However, the greatest intensity of actual motor neuronal lipid peroxidative injury is associated with the active phase of disease progression. These findings further support a role of oxygen radical-mediated motor neuronal injury in the pathogenesis of FALS and the potential benefits of antioxidant therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670993     DOI: 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.0.CO;2-H

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  37 in total

Review 1.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

2.  Pharmacological inhibition of lipid peroxidation attenuates calpain-mediated cytoskeletal degradation after traumatic brain injury.

Authors:  Ayman G Mustafa; Juan A Wang; Kimberly M Carrico; Edward D Hall
Journal:  J Neurochem       Date:  2011-03-22       Impact factor: 5.372

3.  Decreased glutathione levels cause overt motor neuron degeneration in hSOD1WT over-expressing mice.

Authors:  Kelby M Killoy; Benjamin A Harlan; Mariana Pehar; Kristi L Helke; Jeffrey A Johnson; Marcelo R Vargas
Journal:  Exp Neurol       Date:  2018-01-04       Impact factor: 5.330

4.  The effect of mild traumatic brain injury on peripheral nervous system pathology in wild-type mice and the G93A mutant mouse model of motor neuron disease.

Authors:  T M Evans; C A Jaramillo; K Sataranatarajan; L Watts; M Sabia; W Qi; H Van Remmen
Journal:  Neuroscience       Date:  2015-04-25       Impact factor: 3.590

5.  Blood volatile organic compounds as potential biomarkers for amyotrophic lateral sclerosis: an animal study in the SOD1 G93A mouse.

Authors:  Hongquan Jiang; Changsong Wang; Ming Ren; Xiang Yin; Chunjie Chi; Lei Guo; Chaofu Ke; Honglin Feng; Enyou Li
Journal:  J Mol Neurosci       Date:  2014-04-09       Impact factor: 3.444

Review 6.  Mutant CuZn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  Enhanced free radical generation of FALS-associated Cu,Zn-SOD mutants.

Authors:  M B Yim; H S Yim; P B Chock; E R Stadtman
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

Review 8.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Direct magnetic resonance evidence for peroxymonocarbonate involvement in the cu,zn-superoxide dismutase peroxidase catalytic cycle.

Authors:  Marcelo G Bonini; Scott A Gabel; Kalina Ranguelova; Krisztian Stadler; Eugene F Derose; Robert E London; Ronald P Mason
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

10.  Mutant Cu,Zn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  Age (Omaha)       Date:  1998-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.